May 21st 2024
During a Case-Based Roundtable® event, Sumanta K. Pal, MD, moderated a discussion on quality of life data and experiences with dose discontinuation of frontline combination therapy for patients with renal cell carcinoma.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Risk Stratification Influences Choice of Frontline IO/TKI Regimen in mRCC
February 13th 2024During a Targeted Oncology™ Case-Based Roundtable™ event, Rana McKay, MD, moderated a discussion on what role risk stratification plays in selecting frontline therapy for a patient with metastatic renal cell carcinoma. This is the first of 2 articles based on this event.
Read More
Tolerability Concerns Influence Use of Lenvatinib/Everolimus Vs Tivozanib in RCC
February 6th 2024During a Targeted Oncology™ Case-Based Roundtable™ event, Sumanta K. Pal, MD, and participants explored the third-line treatment options for a patient with advanced renal cell carcinoma. This is the second of 2 articles based on this event.
Read More
Beyond Immunotherapy: New RCC Hope With TPST-1120 and Nivolumab Combo
February 4th 2024In an interview with Targeted Oncology, Bruno Bastos, MD, discussed how TPST-1120 can help address limited treatment options for patients with advanced renal cell carcinoma beyond immunotherapy and anti-VEGF tyrosine kinase inhibitors.
Read More
Adjuvant Nivolumab Falls Short of Disease-Free Survival End Point in Locally Advanced High-Risk RCC
January 27th 2024In the phase 3 CheckMate 914 trial, the use of nivolumab did not meet the primary endpoint of disease-free survival when compared to a placebo in patients with localized renal cell carcinoma at a heightened risk of relapse following nephrectomy.
Read More
Lenvatinib/Pembrolizumab Shows Positive Trends vs Global SOC in Frontline RCC Meta-Analysis
January 27th 2024First-line lenvatinib and pembrolizumab showed similar overall survival rates and improved progression-free survival and response rates vs global standard-of-care immunotherapies among patients with advanced renal cell carcinoma.
Read More
Peers Discuss Impressions of Tivozanib’s Role as Third-Line RCC Therapy
January 23rd 2024During a Targeted Oncology™ Case-Based Roundtable™ event, Sumanta K. Pal, MD, discussed the case of an older patient with metastatic renal cell carcinoma who had recurrent disease after receiving axitinib and pembrolizumb, then single-agent cabozantinib. This is the first of 2 articles based on this event.
Read More
TKI and PD-L1 Therapy Combinations Show Long-Term Durability in Advanced RCC
January 17th 2024In this Q&A discussion, Hans Hammers, MD, PhD, explains the rationale for continued use of tyrosine kinase inhibitor and PD-L1 therapy combinations, like lenvatinib and pembrolizumab, for patients with advanced renal cell carcinoma.
Read More
Management of Serious Toxicities with Cabozantinib/Nivolumab in mRCC
January 16th 2024During a Targeted Oncology™ Case-Based Roundtable™ event, Neeraj Agarwal, MD, discussed his approach to recognizing and managing adverse events related to treatment with cabozantinib and nivolumab in patients with advanced renal cell carcinoma. This is the second article based on this event.
Read More
Pembrolizumab/Cabozantinib Shows Encouraging Preliminary Efficacy in mRCC
January 10th 2024Pembrolizumab plus cabozantinib showed promising activity with an objective response rate of 65.8%, median progression-free survival of 10.45 months, and median overall survival of 30.81 months in metastatic renal cell carcinoma.
Read More
Updated Data Shows Durable Efficacy of Cabozantinib/Nivolumab in mRCC
December 21st 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Neeraj Agarwal, MD, examined the significance of the 44-month follow-up of the CheckMate 9ER trial of patients with metastatic renal cell carcinoma.
Read More
Talazoparib/Avelumab Shows No Clinical Benefit in Metastatic Kidney Cancer
December 18th 2023Though the combination of talazoparib and avelumab was safe as a treatment for patients with specific types of kidney cancer, the combination was not effective, according to findings from a phase 2 trial.
Read More
Roundtable Roundup: Choosing Third-Line ccRCC Therapy
December 14th 2023In separate live events, Yasser Mohamed Ali Ged, MBBS, and Deepak Kilari, MD, discussed the best treatment options for patients with advanced renal cell carcinoma and what role tyrosine kinase inhibitors play for these patients.
Read More
Limited Treatment Options in nccRCC Expanding With IO/TKI Combinations
December 12th 2023Clinical trials are shedding light into best treatment approaches for non–clear cell renal cell carcinoma, including immunotherapy plus tyrosine kinase inhibitor combinations, as discussed in Case-Based Roundtable events.
Read More
Interpreting Trial Data on Tolerability in Third-Line mRCC Regimens
November 28th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Pedro C. Barata, MD, MSc, and participants discussed dosing and toxicity issues related to tivozanib and lenvatinib/everolimus in a patient who has received 2 prior lines of therapy for metastatic clear cell renal cell carcinoma.
Read More
Park Considers Long-Term Data for Frontline Metastatic ccRCC Treatment
November 24th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Chandler Park, MD, reviewed the latest updates of the pivotal trials of frontline combination therapies for advanced clear cell renal cell carcinoma.
Read More
Key Efficacy and Tolerability Factors for Later-Line Therapies in RCC
November 16th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Arnab Basu, MD, MPH, and participants discussed issues related to the use of tivozanib and lenvatinib/everolimus as third-line therapies for patients with advanced renal cell carcinoma.
Read More
Understanding Clonal Hematopoiesis in Kidney Cancer Could Improve Cardiovascular Outcomes
November 11th 2023In a presentation at the 2023 International Kidney Cancer Symposium, Maxine Sun, PhD, MPH, discussed the relationship between clonal hematopoiesis in patients with kidney cancer and their risk for cardiac events.
Read More
Comparative Efficacy, Tolerability With RP2D of Belzutifan in LITESPARK-013 Trial for ccRCC
November 11th 2023Results unveiled at the 2023 International Kidney Cancer Symposium revealed that patients with advanced clear cell renal cell carcinoma in the 200-mg dose group achieved an overall response rate of 23.1% based on blinded independent central review.
Read More